DAE HWA Pharmaceutical Co. Ltd
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthriti… Read more
DAE HWA Pharmaceutical Co. Ltd (067080) - Net Assets
Latest net assets as of September 2025: ₩73.73 Billion KRW
Based on the latest financial reports, DAE HWA Pharmaceutical Co. Ltd (067080) has net assets worth ₩73.73 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩206.39 Billion) and total liabilities (₩132.66 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩73.73 Billion |
| % of Total Assets | 35.72% |
| Annual Growth Rate | 1.81% |
| 5-Year Change | -12.17% |
| 10-Year Change | 17.92% |
| Growth Volatility | 5.96 |
DAE HWA Pharmaceutical Co. Ltd - Net Assets Trend (2011–2024)
This chart illustrates how DAE HWA Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DAE HWA Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual net assets of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩72.00 Billion | -1.68% |
| 2023-12-31 | ₩73.23 Billion | -6.10% |
| 2022-12-31 | ₩77.99 Billion | -2.11% |
| 2021-12-31 | ₩79.67 Billion | -2.81% |
| 2020-12-31 | ₩81.98 Billion | +3.32% |
| 2019-12-31 | ₩79.35 Billion | +3.21% |
| 2018-12-31 | ₩76.88 Billion | +0.16% |
| 2017-12-31 | ₩76.75 Billion | +16.03% |
| 2016-12-31 | ₩66.15 Billion | +8.35% |
| 2015-12-31 | ₩61.06 Billion | +4.36% |
| 2014-12-31 | ₩58.51 Billion | -5.68% |
| 2013-12-31 | ₩62.03 Billion | +1.04% |
| 2012-12-31 | ₩61.39 Billion | +7.73% |
| 2011-12-31 | ₩56.99 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to DAE HWA Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3938321155000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩39.38 Billion | 54.70% |
| Common Stock | ₩9.31 Billion | 12.93% |
| Other Components | ₩23.31 Billion | 32.37% |
| Total Equity | ₩72.00 Billion | 100.00% |
DAE HWA Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of DAE HWA Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Meliá Hotels International S.A
PINK:SMIZF
|
$133.45 Million |
|
Stellar V Capital Corp. Class A Ordinary Shares
NASDAQ:SVCC
|
$133.52 Million |
|
Cipher Pharmaceuticals Inc
OTCQX:CPHRF
|
$133.52 Million |
|
Zueblin Immobilien Holding AG
SW:ZUBN
|
$133.64 Million |
|
Kec Corporation
KO:092220
|
$133.40 Million |
|
LIVECHAT SOFTW.AB ZY-02
F:886
|
$133.39 Million |
|
Sterling Bancorp Inc
NASDAQ:SBT
|
$133.34 Million |
|
ZALARIS ASA A NK -10
F:81Y
|
$133.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DAE HWA Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 73,231,783,240 to 71,999,131,410, a change of -1,232,651,830 (-1.7%).
- Net income of 531,415,960 contributed positively to equity growth.
- Dividend payments of 2,627,497,500 reduced retained earnings.
- Other factors increased equity by 863,429,710.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩531.42 Million | +0.74% |
| Dividends Paid | ₩2.63 Billion | -3.65% |
| Other Changes | ₩863.43 Million | +1.2% |
| Total Change | ₩- | -1.68% |
Book Value vs Market Value Analysis
This analysis compares DAE HWA Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.05x to 3.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3746.41 | ₩15170.00 | x |
| 2017-12-31 | ₩4340.27 | ₩15170.00 | x |
| 2018-12-31 | ₩4347.40 | ₩15170.00 | x |
| 2019-12-31 | ₩4622.72 | ₩15170.00 | x |
| 2020-12-31 | ₩4692.74 | ₩15170.00 | x |
| 2021-12-31 | ₩4548.48 | ₩15170.00 | x |
| 2022-12-31 | ₩4452.48 | ₩15170.00 | x |
| 2023-12-31 | ₩4180.70 | ₩15170.00 | x |
| 2024-12-31 | ₩4110.33 | ₩15170.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DAE HWA Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.36%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 2.86x
- Recent ROE (0.74%) is below the historical average (4.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 6.70% | 2.65% | 1.05x | 2.41x | ₩-1.85 Billion |
| 2012 | 5.23% | 2.20% | 1.10x | 2.16x | ₩-2.87 Billion |
| 2013 | 2.77% | 1.31% | 1.05x | 2.02x | ₩-4.36 Billion |
| 2014 | -0.18% | -0.08% | 1.09x | 2.14x | ₩-5.90 Billion |
| 2015 | 6.41% | 2.81% | 1.12x | 2.04x | ₩-2.19 Billion |
| 2016 | 5.64% | 2.62% | 0.93x | 2.33x | ₩-2.89 Billion |
| 2017 | 16.49% | 10.36% | 0.74x | 2.16x | ₩4.98 Billion |
| 2018 | 8.65% | 6.04% | 0.68x | 2.11x | ₩-1.04 Billion |
| 2019 | 13.28% | 9.20% | 0.69x | 2.09x | ₩2.61 Billion |
| 2020 | -2.45% | -1.84% | 0.62x | 2.14x | ₩-10.21 Billion |
| 2021 | 2.78% | 1.89% | 0.66x | 2.23x | ₩-5.75 Billion |
| 2022 | 1.43% | 0.85% | 0.66x | 2.55x | ₩-6.68 Billion |
| 2023 | -1.57% | -0.81% | 0.64x | 2.99x | ₩-8.47 Billion |
| 2024 | 0.74% | 0.36% | 0.73x | 2.86x | ₩-6.67 Billion |
Industry Comparison
This section compares DAE HWA Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DAE HWA Pharmaceutical Co. Ltd (067080) | ₩73.73 Billion | 6.70% | 1.80x | $133.43 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |